Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FALCON: GLPG2451, Galicaftor, and GLPG2737 in Cystic Fibrosis
NCT03540524Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of GLPG2451, galicaftor and GLPG2737 in cystic fibrosis (CF) (3 cohorts), sponsored by Galapagos NV. Primary endpoints: Number of subjects with adverse events up to 24 weeks, Maximum observed plasma concentration at Day 28 and 4 more. Started May 2018; status: completed.
02
Drugs
GLPG2451galicaftorGLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03540524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540524.